Nemaura Stock Analysis

NMRD -  USA Stock  

USD 10.57  0.92  9.53%

The latest price surge of Nemaura Med may encourage shareholders to take a closer look at the firm as it is trading at a share price of 10.57 on 255,835 in trading volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 18.51. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Nemaura Med partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

The Nemaura Med stock analysis report makes it easy to digest most publicly released information about Nemaura Med and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Nemaura stock analysis module also helps to analyze the Nemaura Med price relationship with some important fundamental indicators such as market cap and management efficiency.

Nemaura Stock Analysis Notes

About 62.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.25. Nemaura Med had not issued any dividends in recent years. The entity had 1-10 split on the 5th of December 2019. Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. Nemaura Med operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Nemaura Med contact Dewan Chowdhury at 646 416 8000 or learn more at

Nemaura Med Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Nemaura Med's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Nemaura Med or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Nemaura Med is way too risky over 90 days horizon
Nemaura Med appears to be risky and price may revert if volatility continues
Nemaura Med is unlikely to experience financial distress in the next 2 years
Net Loss for the year was (5.47 M).
Nemaura Med currently holds about 14.96 M in cash with (5.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65.
Nemaura Med has a frail financial position based on the latest SEC disclosures
Roughly 62.0% of the company outstanding shares are owned by corporate insiders
Latest headline from Nemaura Medical Inc falls -9.1280 percent for June 16 -

Nemaura Med SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Nemaura Med prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Nemaura Med investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Nemaura Med specific information freely available to individual and institutional investors to make a timely investment decision.
14th of May 2021
Financial Statements and Exhibits. Regulation FD Disclosure
5th of May 2021
Financial Statements and Exhibits. Other Events
28th of April 2021
Regulation FD Disclosure. Results of Operations and Financial Condition
13th of April 2021
Financial Statements and Exhibits. Other Events
7th of April 2021
Financial Statements and Exhibits. Regulation FD Disclosure
15th of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure
5th of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure
11th of February 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement

Nemaura Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Nemaura Med is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nemaura Med backward and forwards among themselves. Nemaura Med's institutional investor refers to the entity that pools money to purchase Nemaura Med's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares378.6 K2.9 M
Vanguard Group IncCommon Shares159 K1.2 M
Geode Capital Management LlcCommon Shares134.5 KM
State Street CorpCommon Shares106 K810 K
Northern Trust CorpCommon Shares83.8 K641 K
Citadel Advisors LlcCall Options57.3 K438 K
Ars Investment Partners LlcCommon Shares54.5 K417 K
Sabby Management LlcPut Options501383 K
Susquehanna International Group LlpCommon Shares30.9 K236 K
Note, although Nemaura Med's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nemaura Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 281.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nemaura Med's market, we take the total number of its shares issued and multiply it by Nemaura Med's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Nemaura Profitablity

Nemaura Med's profitability indicators refer to fundamental financial ratios that showcase Nemaura Med's ability to generate income relative to its revenue or operating costs. If, let's say, Nemaura Med is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Nemaura Med's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Nemaura Med's profitability requires more research than a typical breakdown of Nemaura Med's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(1.49) (1.53) 
Return on Average Equity 447.32  482.64 
Return on Invested Capital 10.58  11.42 

Management Efficiency

The entity has return on total asset (ROA) of (28.75) % which means that it has lost $28.75 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (108.49) %, meaning that it created substantial loss on money invested by shareholders. Nemaura Med management efficiency ratios could be used to measure how well nemaura med manages its routine affairs as well as how well it operates its assets and liabilities. Nemaura Med Return on Invested Capital is projected to increase significantly based on the last few years of reporting. The past year's Return on Invested Capital was at 10.58. Nemaura Med Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 971,611. The current year Assets Non Current is expected to grow to about 660.8 K, whereas Goodwill and Intangible Assets are forecasted to decline to about 222.6 K.
Last ReportedProjected for 2021
Book Value per Share(0.07) (0.07) 
Enterprise Value over EBIT(28.75) (31.02) 
Enterprise Value over EBITDA(29.45) (31.77) 
Price to Book Value(106.80) (109.61) 
Tangible Assets Book Value per Share 0.06  0.06 
Enterprise Value108.8 M111.6 M
Tangible Asset Value1.2 M1.2 M

Technical Drivers

As of the 20th of June, Nemaura Med secures the Risk Adjusted Performance of 0.0605, mean deviation of 7.76, and Downside Deviation of 7.08. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nemaura Med, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Nemaura Med, which can be compared to its peers in the industry. Please verify Nemaura Med treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Nemaura Med is priced some-what accurately, providing market reflects its recent price of 10.57 per share. Given that Nemaura Med has jensen alpha of 1.51, we recommend you to check Nemaura Med's last-minute market performance to make sure the company can sustain itself at a future point.

Nemaura Med Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Moving Average is predictive technique used to analyze Nemaura Med price data points by creating a series of averages of different subsets of Nemaura Med entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Nemaura Med Technical and Predictive Indicators

Nemaura Med Forecast Models

Nemaura Med time-series forecasting models is one of many Nemaura Med's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nemaura Med's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Nemaura Med Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nemaura Med stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nemaura shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Nemaura Med. By using and applying Nemaura Stock analysis, traders can create a robust methodology for identifying Nemaura entry and exit points for their positions.
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. Nemaura Med operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Nemaura Med to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Comparator Now


Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module
Additionally, see Stocks Correlation. Note that the Nemaura Med information on this page should be used as a complementary analysis to other Nemaura Med's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Nemaura Med Stock analysis

When running Nemaura Med price analysis, check to measure Nemaura Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nemaura Med is operating at the current time. Most of Nemaura Med's value examination focuses on studying past and present price action to predict the probability of Nemaura Med's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nemaura Med's price. Additionally, you may evaluate how the addition of Nemaura Med to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
The market value of Nemaura Med is measured differently than its book value, which is the value of Nemaura that is recorded on the company's balance sheet. Investors also form their own opinion of Nemaura Med's value that differs from its market value or its book value, called intrinsic value, which is Nemaura Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nemaura Med's market value can be influenced by many factors that don't directly affect Nemaura Med underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nemaura Med's value and its price as these two are different measures arrived at by different means. Investors typically determine Nemaura Med value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nemaura Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.